The Europe Thrombosis And Hemostasis Biomarkers Market would witness market growth of 5.4% CAGR during the forecast period (2023-2030).
Venous thromboembolism includes pulmonary embolism (PE) and deep vein thrombosis (DVT). VTE poses a high risk of increased morbidity and death for the great majority of the population due to individual propensity to produce vascular thrombi, as well as clinical situations that further raise this propensity. VTE continues to be a major public health issue, and the general public and healthcare professionals need to be made more aware of it.
An estimated 1/1000 people have acute pulmonary embolism (aPE), one of the primary causes of mortality and morbidity. Within 90 days, there will likely be a 20% mortality rate for aPE. To lower the potential of recurrent venous thromboembolism occurrences, anticoagulation medication for at least 3 months is advised for patients with aPE. However, the odds of VTE recurrence among unprovoked patients with a first aPE are 10% at one year and 36% at ten years after quitting anticoagulant medication.
The Organization for Economic Co-operation and Development (OECD) estimates that in 2019, 32.3 million people in the Member States of the European Union had diabetes, an increase from previous estimates. This rise in prevalence goes hand in hand with the rising trends in bad diets, physical inactivity, socioeconomic deprivation, and obesity and overweight. These risk factors contribute not only to the development of diabetes but also to noncommunicable diseases (NCDs), such as cancer, cardiovascular disease, and chronic respiratory illness. This has prompted the governments of many Member States to introduce policies and initiatives to raise the prevalence of diabetes. Therefore, these precursors will aid the market's growth in the coming years.
The Germany market dominated the Europe Thrombosis And Hemostasis Biomarkers Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $493.7 million by 2030. The UK market is estimated to grow at a CAGR of 4.5% during (2023 - 2030). Additionally, The France market would experience witness a CAGR of 6.2% during (2023 - 2030).
Based on Product, the market is segmented into Reagents & Consumables, and Analyzers. Based on Application, the market is segmented into Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Disseminated Intravascular Coagulation (DIC) & Others. Based on End-use, the market is segmented into Diagnostic Centers, Hospitals & Clinics, and Academic & Research Institutes and Others. Based on Location, the market is segmented into Clinical Laboratory Tests, and Point-of-Care Tests. Based on Type, the market is segmented into Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, D-Dimer, Anti-Thrombin III, Plasminogen & Fibrinogen, Soluble Fibrin, Selectins, Factor VIII, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Thrombosis And Hemostasis Biomarkers Market is Projected to reach USD 7.4 Billion by 2030, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG (Siemens AG), Abbott Laboratories, BioMérieux S.A., Horiba Ltd., QuidelOrtho Corporation, Werfen, S.A., Diazyme Laboratories, Inc. (General Atomics) and BioMedica Diagnostics Inc. (Scotia Investments Family of Companies).
By Product
By Application
By End-Use
By Location
By Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
